Global Multiple Sclerosis Therapeutics Industry

Jun 28, 2010, 12:48 ET from Reportlinker

NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Multiple Sclerosis Therapeutics industry

http://www.reportlinker.com/p0197210/Global-Multiple-Sclerosis-Therapeutics-industry.html

This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

MULTIPLE SCLEROSIS THERAPEUTICS MCP-6311

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET HIGHLIGHTS II-1

Market Snapshots II-1

Market Drivers II-1

Market Restraints II-1

Major Players II-1

2. MARKET OVERVIEW II-2

Increasing Prevalence of Multiple Sclerosis II-2

Table 1: World Multiple Sclerosis Prevalence in Thousands by

Select Countries for Years 2001 through 2010 (includes

corresponding Graph/Chart) II-3

Table 2: Prevalence by Types of Multiple Sclerosis (includes

corresponding Graph/Chart) II-4

MS Therapeutics in the Market II-4

Key Multiple Sclerosis Drugs II-4

Interferon Drugs II-5

Beta Interferon Drugs in Multiple Sclerosis Treatment II-5

Non-Interferon Drugs II-5

Non-Interferon Drugs in Multiple Sclerosis Treatment II-6

High Unmet Need and Rich Pipeline to Expand MS Market II-6

Challenges Ahead II-6

3. MARKET TRENDS II-7

Interferon-based Drugs Dominate Multiple Sclerosis Market II-7

Sales Dip Inevitable for Current Therapies II-7

Tough Times Ahead for Betaseron II-8

Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies II-8

Competitive Landscape II-9

Table 3: Global Multiple Sclerosis Market by Leading Drugs

(2008 & 2009): Percentage Share Breakdown for Copaxone,

Avonex, Rebif, Betaseron, and Tysabri (includes corresponding

Graph/Chart) II-9

4. MULTIPLE SCLEROSIS - DRUG PIPELINE II-11

Recent Clinical Trial Activity - An Overview II-11

Drugs Under Development for Treating Multiple Sclerosis II-12

FTY 720 (Fingolimod) II-13

Mylinax II-13

Laquinimod II-13

Alemtuzumab II-14

Teriflunomide II-14

BG-12 (Oral Fumarate) II-15

MN-166 II-15

Rituxan/MabThera (Rituximab) II-15

Vaccines for Multiple Sclerosis II-16

5. PRODUCT OVERVIEW II-17

Definition II-17

Causes of Multiple Sclerosis II-17

Different Forms of Multiple Sclerosis II-17

Pathology II-18

6. RECENT INDUSTRY ACTIVITY II-19

Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to

treat Multiple Sclerosis II-19

Novartis Obtains Priority Review Status for Oral Fingolimod

from US FDA II-19

Copaxone Receives FDA Approval for Patients with First

Clinical Episode Suggestive of MS II-19

Novartis Obtains FDA Approval for Extavia II-20

Merck Serono Collaborates with Brigham and Women's Hospital to

Extend Multiple Sclerosis Research II-20

Merck Serono Announces Encouraging Phase III Results of Oral

Mylinax II-20

Merck Serono Acquires Rights to Apitope's Multiple Sclerosis

Approach II-21

Teva and Active Biotech Obtains Fast Track Status from FDA for

Oral Laquinimod II-21

Genzyme Signs an Agreement with Bayer Healthcare II-21

EMD Serono to Set Up Research Facility in Massachusetts II-22

EMD Serono Enters into a Partnership with Fast Forward II-22

Biogen Idec Secures US-FDA Approval for Production Process of

TYSABRI® II-23

Biogen Idec Secures Fast Track Designation from US-FDA for

PEGylated Interferon Beta-1a II-23

Bayer Schering Pharma Receives SFDA of China Approval for

Betaferon® II-23

Merck Serono Signs an Agreement with Bionomics II-24

Orasi Medical Establishes New Office in Tokyo II-24

Merck Serono and Ambrx to Extend Collaboration for Multiple

Sclerosis II-25

Kineta Acquires Novel Therapeutic Compounds from Airmid II-25

MediciNova Enters into Agreement with Avigen II-25

Biogen Idec Takes Over Facet Biotech II-26

Teva Pharmaceutical Industries to Take over CoGenesys II-26

Merck Serono Introduces RebiSmartTM Electronic Injection Device II-26

Bayer to Launch Betaferon Titration Pack II-26

MediciNova Announces Phase II Clinical Trial Results of MN-166 II-26

The Myelin Repair Foundation Signs Strategic Deal with Dalton

Pharma Services II-27

Acorda Therapeutics Takes Over Neurorecovery II-27

Bayer to Introduce 30-Gauge Needle for Betaferon® II-27

Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12 II-28

Bayer Acquires Biologics Manufacturing Plant from Novartis II-28

7. FOCUS ON SELECT PLAYERS II-29

Bayer Schering Pharma AG (Germany) II-29

Biogen Idec Inc. (US) II-29

Elan Pharmaceuticals, Inc. (US) II-30

Genzyme Corp. (US) II-30

Merck Serono SA (Switzerland) II-30

Novartis AG (Switzerland) II-31

Sanofi-Aventis SA (France) II-31

Teva Pharmaceuticals Industries Limited (Israel) II-32

8. GLOBAL MARKET PERSPECTIVE II-33

Table 4: World Recent Past, Current & Future Analysis for

Multiple Sclerosis Therapeutics by Geographic Region - US,

Japan, Europe and Rest of World- Markets Independently

Analyzed with Annual Sales in US$ Billion for Years 2006

through 2015 (includes corresponding Graph/Chart) II-33

Table 5: World 10-year Perspective for Multiple Sclerosis

Therapeutics by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Japan, Europe and Rest of World Markets

for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-34

Table 6: World Recent Past, Current & Future Analysis for

Multiple Sclerosis Therapeutics by Leading Drugs - Copaxone,

Avonex, Rebif, Betaseron, Tysabri, and Other Drugs

Independently Analyzed with Annual Sales in US$ Billion for

Years 2006 through 2015 (includes corresponding Graph/Chart) II-35

Table 7: World 10-year Perspective for Multiple Sclerosis

Therapeutics by Leading Drugs - Percentage Breakdown of

Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri,

and Other Drugs for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) II-36

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Overview III-1

Table 8: US Multiple Sclerosis Prevalence in Thousands for

Years 2001 through 2010 (includes corresponding

Graph/Chart) III-1

Strategic Corporate Developments III-1

Key Players III-7

Biogen Idec, Inc. III-7

Elan Pharmaceuticals, Inc. III-8

EMD Serono, Inc. III-8

Genzyme Corp. III-9

B.Market Analytics III-9

Table 9: US Recent Past, Current & Future Analysis for

Multiple Sclerosis Therapeutics Market Analyzed with Annual

Sales Figures in US$ Billion for Years 2006 through 2015

(includes corresponding Graph/Chart) III-9

2. JAPAN III-10

A.Market Analysis III-10

Overview III-10

Table 10: Japanese Multiple Sclerosis Prevalence in

Thousands for Years 2001 through 2010 (includes

corresponding Graph/Chart) III-10

Strategic Corporate Development III-10

B.Market Analytics III-11

Table 11: Japanese Recent Past, Current & Future Analysis

for Multiple Sclerosis Therapeutics Market Analyzed with

Annual Sales Figures in US$ Billion for Years 2006 through

2015 (includes corresponding Graph/Chart) III-11

3. EUROPE III-12

A.Market Analysis III-12

Overview III-12

Table 12: Multiple Sclerosis Prevalence in Select European

Countries for Years 2001 through 2010 (includes

corresponding Graph/Chart) III-12

Low Penetration to Fuel Growth in European MS DMDs Market III-12

Oral Medication for MS in Near Future III-13

Strategic Corporate Development III-13

Key Players III-14

Bayer Schering Pharma AG (Germany) III-14

Merck Serono SA (Switzerland) III-14

Novartis AG (Switzerland) III-14

Sanofi-Aventis SA (France) III-15

B.Market Analytics III-16

Table 13: European Recent Past, Current & Future Analysis

for Multiple Sclerosis Therapeutics Market Analyzed with

Annual Sales Figures in US$ Billion for Years 2006 through

2015 (includes corresponding Graph/Chart) III-16

4. REST OF WORLD III-17

A.Market Analysis III-17

Overview III-17

Increasing Incidence of Multiple Sclerosis in Canada III-17

Strategic Corporate Developments III-17

Key Player III-18

Teva Pharmaceuticals Industries Limited (Israel) III-18

B.Market Analytics III-19

Table 14: Rest of World Recent Past, Current & Future

Analysis for Multiple Sclerosis Therapeutics Market

Analyzed with Annual Sales Figures in US$ Billion for Years

2006 through 2015 (includes corresponding Graph/Chart) III-19

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 45 (including Divisions/Subsidiaries - 51)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 26

Canada 3

Japan 1

Europe 18

France 1

Germany 4

The United Kingdom 3

Rest of Europe 10

Asia-Pacific (Excluding Japan) 2

Middle East 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global Multiple Sclerosis Therapeutics industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com